MD SHAHADAT HOSSAN

Dr. Md Shahadat Hossan was born in Brahmamnbaria, Bangladesh. He obtained a Bachelor of Pharmacy at the University of Development Alternative, Dhaka, Bangladesh, while conducting undergraduate research under the supervision of renowned scientist Professor Dr. Mohammed Rahmatullah where he started publishing 1st author and co-authored peer-reviewed papers in international journals. Having been inspired by his laboratory research project in natural product drug discovery and excited about designing small molecule drugs, specifically to fight against cancer and microbial diseases, he moved to the UK to continue his research and education. He received his Ph.D. from the School of Pharmacy, University of Nottingham, UK with Professor Christophe Wiart and Dr. Tracey Bradshaw. His Ph.D. work has encompassed studying the anticancer and antimicrobial properties of uncharacterized and novel natural products derived from plants. He possesses the cross – and multidisciplinary expertise associated with natural product drug discovery, especially cancer drug discovery, and moreover excels in these disciplines in molecular and cellular biology, intracellular signaling pathways, molecular genetics in relation to pharmacology, cell cycle regulation, and biochemical and analytical methods. His Ph.D. work has been published in Cancer Letters (2019), Book chapter in CRC press (2018), Experimental Parasitology (2018), Archive of Virology (2018), Fitotherapia (2018), Pharmacological Biology (2018), Journal of Ethnopharmacology (2017) and presented in international conferences (2018). He worked as a research and teaching assistant at the School of Pharmacy, University of Nottingham (2015-2017) and as an honorarium research assistant at the University of Malaya (2015). Further inspired by this to pursue a career working on cancer drugs, Shahadat then started a postdoctoral research fellow position in February 2020 at the School of Pharmacy, the University of Nottingham to investigate the mechanism of action of experimental anticancer and anti-Nash compounds. He also investigated the effects of different formulations on the membrane permeability of a lead natural product and drug candidate. In January 2022, he started working as a postdoctoral research associate with Jeremy Kratz, MD at the Department of Medicine, University of Wisconsin Madison. Dr. Hossan has been promoted as Scientist II from 1st January 2023. By focusing efforts on patient-derived tissues, the goal of the Kratz laboratory is to characterize pathways with the greatest opportunity to translate to effective therapies in early-phase clinical trials. Dr. Hossan is involved in the therapeutic development of pancreatic and liver cancers. He works on the project to develop ex vivo tools for the prediction of targeted therapeutic responses and overcoming secondary mechanisms of resistance. Investigating the spectrum of anticancer activity of experimental agents to identify molecular mechanisms of action, imaging, as well as patient-derived cancer organoid banking, achieving fully synthetic organoid cultures and targeting RNA transcription. He is also involved with different projects such as next-generation sequencing, broad expression profiling, high-throughput screening, advanced microscopy, and animal models.